目次

1. Executive Summary
1.1.Regional Market Share
1.2. Business Trends
1.3.Antimicrobial Therapeutics Market: COVID-19 Outbreak
1.4.Regional Trends
1.5. Segmentation Snapshot

2. Research Methodology
2.1. Research Objective
2.2.Research Approach
2.3.Data Sourcing and Methodology
2.4. Primary Research
2.5. Secondary Research
2.5.1. Paid Sources
2.5.2.Public Sources
2.6.Market Size Estimation and Data Triangulation

3. Market Characteristics
3.1. Market Definition
3.2.Antimicrobial Therapeutics Market: COVID-19 Impact
3.3.Key Segmentations
3.4. Key Developments
3.5. Allied Industry Data

4. Antimicrobial Therapeutics Market - Industry Insights
4.1.Industry Segmentation
4.2. COVID-19 overview of world economy
4.3. Industry Ecosystem Channel Analysis
4.4. Innovation & Sustainability

5. Macroeconomic Indicators

6. Recent Developments
7.Market Dynamics
7.1. Introduction
7.2.Growth Drivers
7.3.Market Opportunities
7.4. Market Restraints
7.5.Market Trends

8. Risk Analysis

9. Market Analysis
9.1. Porter's Five Forces
9.2.PEST Analysis
9.2.1. Political
9.2.2.Economic
9.2.3.Social
9.2.4.Technological

10. Antimicrobial Therapeutics Market
10.1.Overview
10.2. Historical Analysis (2019-2022)
10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
11.Antimicrobial Therapeutics Market Size & Forecast 2024A-2034F
11.1.Overview
11.2. Key Findings
11.3. Market Segmentation
11.3.1. By Drug Class
11.3.1.1. Antibacterial
11.3.1.1.1. By Value (USD Million) 2024-2034F
11.3.1.1.2.Market Share (%) 2024-2034F
11.3.1.1.3.Y-o-Y Growth (%) 2024-2034F
11.3.1.2.Antivirals
11.3.1.2.1.By Value (USD Million) 2024-2034F
11.3.1.2.2. Market Share (%) 2024-2034F
11.3.1.2.3. Y-o-Y Growth (%) 2024-2034F
11.3.1.3.Antifungal
11.3.1.3.1.By Value (USD Million) 2024-2034F
11.3.1.3.2. Market Share (%) 2024-2034F
11.3.1.3.3. Y-o-Y Growth (%) 2024-2034F
11.3.1.4.Antiparasitic
11.3.1.4.1.By Value (USD Million) 2024-2034F
11.3.1.4.2. Market Share (%) 2024-2034F
11.3.1.4.3. Y-o-Y Growth (%) 2024-2034F
11.3.2. By Route of Administration
11.3.2.1.Oral
11.3.2.1.1.By Value (USD Million) 2024-2034F
11.3.2.1.2. Market Share (%) 2024-2034F
11.3.2.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.2.2. Tropic
11.3.2.2.1. By Value (USD Million) 2024-2034F
11.3.2.2.2.Market Share (%) 2024-2034F
11.3.2.2.3.Y-o-Y Growth (%) 2024-2034F
11.3.2.3. Injectable
11.3.2.3.1. By Value (USD Million) 2024-2034F
11.3.2.3.2.Market Share (%) 2024-2034F
11.3.2.3.3.Y-o-Y Growth (%) 2024-2034F
11.3.2.4. Others
11.3.2.4.1. By Value (USD Million) 2024-2034F
11.3.2.4.2.Market Share (%) 2024-2034F
11.3.2.4.3. Y-o-Y Growth (%) 2024-2034F
11.3.3. By Disease Indication
11.3.3.1.Respiratory Infections
11.3.3.1.1.By Value (USD Million) 2024-2034F
11.3.3.1.2. Market Share (%) 2024-2034F
11.3.3.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.2. Urinary Tract Infections
11.3.3.2.1. By Value (USD Million) 2024-2034F
11.3.3.2.2.Market Share (%) 2024-2034F
11.3.3.2.3.Y-o-Y Growth (%) 2024-2034F
11.3.3.3. Skin and Soft Tissue Infections
11.3.3.3.1. By Value (USD Million) 2024-2034F
11.3.3.3.2.Market Share (%) 2024-2034F
11.3.3.3.3.Y-o-Y Growth (%) 2024-2034F
11.3.3.4. Sexually Transmitted Infections
11.3.3.4.1. By Value (USD Million) 2024-2034F
11.3.3.4.2. Market Share (%) 2024-2034F
11.3.3.4.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.5. Gastrointestinal Infections
11.3.3.5.1. By Value (USD Million) 2024-2034F
11.3.3.5.2.Market Share (%) 2024-2034F
11.3.3.5.3.Y-o-Y Growth (%) 2024-2034F
11.3.3.6. Central Nervous System Infections
11.3.3.6.1. By Value (USD Million) 2024-2034F
11.3.3.6.2.Market Share (%) 2024-2034F
11.3.3.6.3.Y-o-Y Growth (%) 2024-2034F
11.3.3.7. Others
11.3.3.7.1. By Value (USD Million) 2024-2034F
11.3.3.7.2.Market Share (%) 2024-2034F
11.3.3.7.3.Y-o-Y Growth (%) 2024-2034F

12. North America Antimicrobial Therapeutics Market Size & Forecast 2024A-2034F
12.1. Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1. By Drug Class
12.3.2.By Route of Administration
12.3.3.By Disease Indication
12.4. Country
12.4.1. United States
12.4.2.Canada

13. Europe Antimicrobial Therapeutics Market Size & Forecast 2024A-2034F
13.1. Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1. By Drug Class
13.3.2.By Route of Administration
13.3.3.By Disease Indication
13.4. Country
13.4.1.Germany
13.4.2.United Kingdom
13.4.3.France
13.4.4. Italy
13.4.5.Spain
13.4.6.Russia
13.4.7.Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)

14. Asia-Pacific Antimicrobial Therapeutics Market Size & Forecast 2024A-2034F
14.1.Overview
14.2. Key Findings
14.3. Market Segmentation
14.3.1. By Drug Class
14.3.2.By Route of Administration
14.3.3.By Disease Indication
14.4. Country
14.4.1. India
14.4.2.China
14.4.3. South Korea
14.4.4. Japan
14.4.5. Rest of APAC

15. Middle East and Africa Antimicrobial Therapeutics Market Size & Forecast 2024A-2034F
15.1.Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1. By Drug Class
15.3.2.By Route of Administration
15.3.3.By Disease Indication
15.4. Country
15.4.1. Israel
15.4.2.GCC
15.4.3.North Africa
15.4.4. South Africa
15.4.5.Rest of Middle East and Africa

16. Latin America Antimicrobial Therapeutics Market Size & Forecast 2024A-2034F
16.1. Overview
16.2. Key Findings
16.3. Market Segmentation
16.3.1. By Drug Class
16.3.2.By Route of Administration
16.3.3.By Disease Indication
16.4. Country
16.4.1. Mexico
16.4.2.Brazil
16.4.3.Rest of Latin America

17. Competitive Landscape
17.1. Company market share, 2023
17.2.Key player overview
17.3. Key stakeholders

18. Company Profiles
18.1. Pfizer Inc.
18.1.1.Company Overview
18.1.2.Financial Overview
18.1.3.Key Product; Analysis
18.1.4.Company Assessment
18.1.4.1.Product Portfolio
18.1.4.2. Key Clients
18.1.4.3. Market Share
18.1.4.4. Recent News & Development (Last 3 Yrs.)
18.1.4.5. Executive Team
18.2.Merck & Co., Inc.
18.3.GlaxoSmithKline plc (GSK)
18.4.Johnson & Johnson
18.5.Novartis International AG
18.6.Sanofi S.A.
18.7.Roche Holding AG
18.8.AstraZeneca PLC
18.9.Bayer AG
18.10.AbbVie Inc.
18.11. Bristol Myers Squibb Company
18.12.Eli Lilly and Company
18.13.Astellas Pharma Inc.
18.14.Gilead Sciences, Inc.
18.15.Boehringer Ingelheim GmbH
18.16.Other Prominent Players

19. Appendix
20.Consultant Recommendation